Results 11 to 20 of about 23,468 (210)

Impact of Coronary Microvascular Dysfunction on Left Ventricular Function After Percutaneous Coronary Intervention: Assessment With Combined Dipyridamole-Exercise Stress and Myocardial Strain/Work. [PDF]

Echocardiography
Decreased coronary flow velocity reserve (CFVR) was correlated with left ventricular (LV) dysfunction after percutaneous coronary intervention (PCI), as assessed via dipyridamole‐exercise stress echocardiography (DExE). This dysfunction was characterized by lower myocardial strain/work index and worse 1‐year Seattle Angina Questionnaire (SAQ) scores ...
Zhao W, Dong X, Ji X, Tang J, Ding L, Zhou Y, Yu S, Li J, Li H, Yang C, Guo Q, Luo Z, Shen Y.   +12 more
europepmc   +2 more sources

Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era

Cardiovascular Drugs and Therapy, 2021
Dipyridamole is an old anti-platelet and coronary vasodilator agent that inhibits platelet phosphodiesterase and increases interstitial adenosine levels.
Mahmoud Allahham, A. Lerman, D. Atar, Y. Birnbaum   +3 more
semanticscholar   +1 more source

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Acta Pharmaceutica Sinica B, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction.
Xiaoyan Liu, Zhe Li, Shuai Liu, Jing Sun, Zhanghua Chen, M. Jiang, Qingling Zhang, Yinghua Wei, Xin Wang, Yiyou Huang, Yinyi Shi, Yanhui Xu, Huifang Xian, F. Bai, C. Ou, Bei Xiong, A. Lew, J. Cui, R. Fang, Hui Huang, Jincun Zhao, Xuechuan Hong, Yuxia Zhang, F. Zhou, Hai-bin Luo   +24 more
semanticscholar   +1 more source

Dipyridamole Inhibits Lipogenic Gene Expression by Retaining SCAP-SREBP in the Endoplasmic Reticulum.

Cell Chemical Biology, 2020
Sterol regulatory element-binding proteins (SREBPs) are master transcriptional regulators of the mevalonate pathway and lipid metabolism and represent an attractive therapeutic target for lipid metabolic disorders.
Ryan M Esquejo, Manuel Roqueta‐Rivera, W. Shao, Peter E. Phelan, Uthpala I. Seneviratne, Christopher W. am Ende, P. Hershberger, C. Machamer, P. Espenshade, T. Osborne   +9 more
semanticscholar   +1 more source

Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.

Current pharmaceutical design, 2020
BACKGROUND COVID-19 pandemic is caused by coronavirus that is also known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The viral infection continues to impact the globe with no vaccine to prevent the infection or highly effective ...
Kholoud F. Aliter, Rami A. Al‐Horani
semanticscholar   +1 more source

Cyclic AMP‐hydrolyzing phosphodiesterase inhibitors potentiate statin‐induced cancer cell death

Molecular Oncology, 2020
Dipyridamole, an antiplatelet drug, has been shown to synergize with statins to induce cancer cell‐specific apoptosis. However, given the polypharmacology of dipyridamole, the mechanism by which it potentiates statin‐induced apoptosis remains unclear ...
Joseph Longo, Aleksandra A. Pandyra, Paweł Stachura, Mark D. Minden, Aaron D. Schimmer, Linda Z. Penn   +5 more
doaj   +1 more source

Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors

Frontiers in Cardiovascular Medicine, 2022
IntroductionCardiovascular events are common in COVID-19. While the use of anticoagulation during hospitalization has been established in current guidelines, recommendations regarding antithrombotic therapy in the post-discharge period are conflicting ...
Lukas J. Motloch, Peter Jirak, Moritz Mirna, Lukas Fiedler, Lukas Fiedler, Paruir A. Davtyan, Irina A. Lakman, Irina A. Lakman, Diana F. Gareeva, Anton V. Tyurin, Ruslan M. Gumerov, Simon T. Matskeplishvili, Valentin N. Pavlov, Benzhi Cai, Kristen Kopp, Albert Topf, Uta C. Hoppe, Rudin Pistulli, Naufal S. Zagidullin   +18 more
doaj   +1 more source

Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease

Kaohsiung Journal of Medical Sciences, 2014
Dipyridamole has been shown to decrease proteinuria and improve renal function progression especially in early chronic kidney disease (CKD) patients with glomerulonephropathy.
Chi-Chih Hung, Mei-Li Yang, Ming-Yen Lin, Hugo You-Hsien Lin, Lee-Moay Lim, Hung-Tien Kuo, Shang-Jyh Hwang, Jer-Chia Tsai, Hung-Chun Chen   +8 more
doaj   +1 more source

XIAP Deficiency Impairs Colonic Tuft Cell Development and Predisposes to Crohn's Disease. [PDF]

MedComm (2020)
XIAP deficiency leads to impaired colonic tuft cells development and JAK–‐STAT pathway hyperactivation in CD patients and mice. Mechanically, XIAP regulates tuft cells development through Wnt–‐TLE4/TCF–‐ASCL2 signaling. Tuft cells deficiency predisposes XIAP‑‐deficient CD patients or Xiap−/−‐/‐ mice to hazardous microbial effects, driving colonic ...
Fang R, Wang W, Zhang L, Huang J, Huang L, Wu H, Qi Y, Li L, Tan L, Zhang M, Zhu J, Peng X, Zhong K, Zou M, Yang X, Wang Q, Nie C, Tang C, Tang N, Geng L, Chen H, Vince JE, Kanegane H, Zhao X, Xian H, Zhou W, Zhi M, Zhang Y, Chen Z.   +28 more
europepmc   +2 more sources

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.

The Lancet, 2018
BACKGROUND Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia.
P. Bath, L. Woodhouse, J. Appleton, M. Beridze, H. Christensen, R. Dineen, L. Duley, T. England, K. Flaherty, D. Havard, S. Heptinstall, M. James, K. Krishnan, H. Markus, A. Montgomery, S. Pocock, M. Randall, A. Ranta, T. Robinson, Polly Scutt, G. Venables, N. Sprigg   +21 more
semanticscholar   +1 more source